- Home
- NRT vs OCUP Comparison
NRT vs OCUP Comparison
Compare NRT & OCUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRT
- OCUP
- Stock Information
- Founded
- NRT 1975
- OCUP 2018
- Country
- NRT United States
- OCUP United States
- Employees
- NRT N/A
- OCUP N/A
- Industry
- NRT Oil & Gas Production
- OCUP Biotechnology: Pharmaceutical Preparations
- Sector
- NRT Energy
- OCUP Health Care
- Exchange
- NRT Nasdaq
- OCUP Nasdaq
- Market Cap
- NRT 47.1M
- OCUP 53.1M
- IPO Year
- NRT N/A
- OCUP N/A
- Fundamental
- Price
- NRT $5.52
- OCUP $1.32
- Analyst Decision
- NRT
- OCUP Strong Buy
- Analyst Count
- NRT 0
- OCUP 3
- Target Price
- NRT N/A
- OCUP $18.67
- AVG Volume (30 Days)
- NRT 34.7K
- OCUP 85.2K
- Earning Date
- NRT 11-15-2024
- OCUP 11-11-2024
- Dividend Yield
- NRT 15.27%
- OCUP N/A
- EPS Growth
- NRT N/A
- OCUP N/A
- EPS
- NRT 0.48
- OCUP N/A
- Revenue
- NRT $5,177,424.00
- OCUP $16,449,000.00
- Revenue This Year
- NRT N/A
- OCUP N/A
- Revenue Next Year
- NRT N/A
- OCUP $258.69
- P/E Ratio
- NRT $11.10
- OCUP N/A
- Revenue Growth
- NRT N/A
- OCUP N/A
- 52 Week Low
- NRT $4.77
- OCUP $1.15
- 52 Week High
- NRT $11.95
- OCUP $3.53
- Technical
- Relative Strength Index (RSI)
- NRT 56.78
- OCUP 48.70
- Support Level
- NRT $5.19
- OCUP $1.25
- Resistance Level
- NRT $5.34
- OCUP $1.35
- Average True Range (ATR)
- NRT 0.18
- OCUP 0.08
- MACD
- NRT 0.06
- OCUP 0.01
- Stochastic Oscillator
- NRT 94.92
- OCUP 29.17
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.